Pulmonary Fibrosis 360

Main navigation

Home

Role of fibrosis

Progressive fibrotic phenotype

Anti-fibrotic treatment

Holistic care

Clinical pathway

Resources

Guidelines

This website is owned and developed by Boehringer Ingelheim and contains promotional information.
This website is only intended for Healthcare Professionals in Ireland. If you are not a Healthcare Professional in Ireland please click here.
Click here for OFEV® (nintedanib) Ireland prescribing information. Find adverse event reporting information at the bottom of this page.

Resources

Resources
Ireland Resources
Sounds of IPF

Sounds of IPF

The sounds of Idiopathic Pulmonary Fibrosis (IPF)

IPF is not just a challenging disease, it is also difficult to diagnose. Early symptoms such as dyspnoea on exertion and dry cough can be misdiagnosed as part of another respiratory disease. The assessment of "Velcro® crackles" by lung auscultation is currently the only realistic means for the earlier diagnosis of Idiopathic Pulmonary Fibrosis (IPF).¹

Use the following example patient sounds to compare the differences between IPF, chronic obstructive pulmonary disease (COPD) and those of a healthy person.

Take the IPF sound challenge

The IPF sound challenge allows you to practice identifying various respiratory conditions, including IPF.

0% complete

Questions 1 of 5

Questions 2 of 5

Questions 3 of 5

Questions 4 of 5

Questions 5 of 5

Take the IPF sound challenge

The IPF sound challenge allows you to practice identifying various respiratory conditions, including IPF.

Results

Chellenge completed. Results are being recorded.

Your Time:

Your Result

Your Answers

Questions 1 of 5

Questions 2 of 5

Questions 3 of 5

Questions 4 of 5

Questions 5 of 5

Question 1 0f 5
- Healthy INCORRCT ANSWER
- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis (IPF)
- Other CORRCT ANSWER
Question 2 0f 5
- Healthy
- Chronic obstructive pulmonary disease (COPD) CORRCT ANSWER
- Idiopathic pulmonary fibrosis (IPF)
- Other
Question 3 0f 5
- Healthy
- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis (IPF) CORRCT ANSWER
- Other
Question 4 0f 5
- Healthy CORRCT ANSWER
- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis (IPF)
- Other CORRCT ANSWER
Question 5 0f 5
- Healthy INCORRCT ANSWER
- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis (IPF)
- Other CORRCT ANSWER

Cottin V, et al. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012;40:519–521.
OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 291 3960 or by email to PV_local_uk_ireland@boehringer-ingelheim.com.

OFEV® (nintedanib) is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. The recommended dose is one 150 mg capsule taken twice daily.²

PC-IE-101269 | June 2022

Privacy policy
Terms of use
Sitemap
Contact us
Cookies policy
Accessibility statement

This information is for healthcare professionals in Ireland only. Products discussed herein may have different labelling in different countries.
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice.

PC-GB-104222 v2 | August 2023

INPULSIS®

Study design
Two replicate 52-week, randomised, double-blind, phase 3 trials (INPULSIS®-1 and INPULSIS®-2) at 205 sites in 24 countries

Study population
Patients diagnosed with idiopathic pulmonary fibrosis (IPF) within the previous 5 years

Treatment arms
OFEV® 150 mg twice daily (n=638) or placebo (n=423)

Primary end-point
Annual rate of decline in the forced vital capacity (FVC), as assessed over a 52-week period

Key secondary end-points (measured at week 52)
Time to the first acute exacerbation change from baseline in the total score on the St. George’s Respiratory Questionnaire

Inclusion criteria
Patients were 40 years of age or older and had received a diagnosis of idiopathic pulmonary fibrosis within the previous 5 years. FVC was 50% or more of the predicted value, diffusion capacity of the lung for carbon monoxide (DLCO) was 30 to 79% of the predicted value, and high-resolution computed tomography (HRCT) of the chest performed within the previous 12 months

Exclusion criteria
Concomitant therapy with up to 15 mg of prednisolone per day, or the equivalent, was permitted if the dose had been stable for 8 or more weeks before screening; patients receiving other therapies for idiopathic pulmonary fibrosis, including high-dose prednisolone, azathioprine, N-acetylcysteine, and any investigational treatments for idiopathic pulmonary fibrosis, were excluded

Reference: Richeldi L et al. N Engl J Med 2014;370:2071-2082.

INBUILD®

Study design

52-week, randomised, double-blind, placebo-controlled, phase 3 trial conducted in 15 countries

Study population

Patients with chronic progressive fibrotic ILDs, excluding patients with idiopathic pulmonary fibrosis (IPF)

Treatment arms

OFEV® 150 mg twice daily (n=332) or placebo (n=331)

Primary end-point

Annual rate of decline in the forced vital capacity (FVC), as assessed over a 52-week period

Key secondary end-points (measured at week 52)

Absolute change from baseline in the total score on the King’s Brief Interstitial Lung Disease (K-BILD) questionnaire

Time until the first acute exacerbation of interstitial lung disease or death

Time until death

Clinical ILD diagnoses for the INBUILD® study population

Inclusion criteria
Patients were required to meet at least one of the following criteria for progression of interstitial lung disease within the 24 months before screening, despite standard treatment with an agent other than nintedanib or pirfenidone: a relative decline in the FVC of at least 10% of the predicted value, a relative decline in the FVC of 5% to less than 10% of the predicted value and worsening of respiratory symptoms or an increased extent of fibrosis on high-resolution CT, or worsening of respiratory symptoms and an increased extent of fibrosis. At the time of enrollment, patients were required to have an FVC of at least 45% of the predicted value and a diffusing capacity of the lung for carbon monoxide (corrected for hemoglobin) of 30 to less than 80% of the predicted value. Enrolled patients had features of fibrotic lung disease affecting more than 10% of lung volume on high-resolution CT.

Exclusion criteria

Patients who were treated with azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, rituximab, cyclophosphamide, or oral glucocorticoids (at a dose of more than 20 mg per day for glucocorticoids) were excluded. These medicines were later permitted at the discretion of the investigator, following 6 months of study treatment.

Because patients with IPF had already been studied, specific efforts were made to enroll patients with a chronic progressive fibrotic phenotype other than IPF

Reference: Flaherty KR et al. N Engl J Med 2019;381:1718-1727 (and supplementary appendix).

Resources

Sounds of IPF

The sounds of Idiopathic Pulmonary Fibrosis (IPF)

Take the IPF sound challenge

Questions 1 of 5

Questions 2 of 5

Questions 3 of 5

Questions 4 of 5

Questions 5 of 5

Take the IPF sound challenge

Results

Your Result

Your Answers

Questions 1 of 5

Questions 2 of 5

Questions 3 of 5

Questions 4 of 5

Questions 5 of 5

References

INPULSIS®

INBUILD®